Screening for synergistic activity of antimicrobial combinations against carbapenem-resistant Enterobacteriaceae using inkjet printer-based technology

被引:40
作者
Brennan-Krohn, Thea [1 ,2 ]
Truelson, Katherine A. [1 ,3 ]
Smith, Kenneth P. [1 ]
Kirby, James E. [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA
[2] Boston Childrens Hosp, Div Infect Dis, Boston, MA USA
[3] Boston Univ, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
IN-VITRO EVALUATION; KLEBSIELLA-PNEUMONIAE; POLYMYXIN-B; ACINETOBACTER; EPIDEMIOLOGY; TIGECYCLINE; COLISTIN; INFECTIONS; FOSFOMYCIN; MEROPENEM;
D O I
10.1093/jac/dkx241
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Synergistic combination antimicrobial therapy may provide new options for treatment of MDR infections. However, comprehensive in vitro synergy data are limited and facile methods to perform synergy testing in a clinically actionable time frame are unavailable. Objectives: To systematically investigate a broad range of antibiotic combinations for evidence of synergistic activity against a collection of carbapenem-resistant Enterobacteriaceae (CRE) isolates. Methods: We made use of an automated method for chequerboard array synergy testing based on inkjet printer technology in the HP D300 digital dispenser to test 56 pairwise antimicrobial combinations of meropenem, aztreonam, cefepime, colistin, gentamicin, levofloxacin, chloramphenicol, fosfomycin, trimethoprim/sulfamethoxazole, minocycline and rifampicin, as well as the double carbapenem combination of meropenem and ertapenem. Results: In a screening procedure, we tested these combinations against four CRE strains and identified nine antibiotic combinations that showed potential clinically relevant synergy. In confirmatory testing using 10 CRE strains, six combinations demonstrated clinically relevant synergy with both antimicrobials at the minimum fractional inhibitory concentration (FICI-MIN) in the susceptible or intermediate range in at least one trial. These included two novel combinations: minocycline plus colistin and minocycline plus meropenem. In 80% of strains at least one combination demonstrated clinically relevant synergy, but the combinations that demonstrated synergy varied from strain to strain. Conclusions: This work establishes the foundation for future systematic, broad-range investigations into antibiotic synergy for CRE, emphasizes the need for individualized synergy testing and demonstrates the utility of inkjet printer-based technology for the performance of automated antimicrobial synergy assays.
引用
收藏
页码:2775 / 2781
页数:7
相关论文
共 44 条
[1]   Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae [J].
Albiero, James ;
Sy, Sherwin K. B. ;
Mazucheli, Josmar ;
Caparroz-Assef, Silvana Martins ;
Costa, Bruno Buranello ;
Borges Alves, Janio Leal ;
Gales, Ana Cristina ;
Bronharo Tognim, Maria Cristina .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (07) :4128-4139
[2]   Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study [J].
Alves, Marcelle D. ;
Ribeiro, Vanessa B. ;
Tessari, Jardel P. ;
Mattiello, Francine ;
De Bacco, Giordanna ;
Luz, Daniela I. ;
Vieira, Fabiane J. ;
Behle, Taina F. ;
Pasqualotto, Alessandro C. ;
Zavascki, Alexandre P. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (06) :1681-1687
[3]  
Bercot B, 2011, J ANTIMICROB CHEMOTH
[4]   Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY:: molecular epidemiology and in vitro activity of polymyxin B and other agents [J].
Bratu, S ;
Tolaney, P ;
Karumudi, U ;
Quale, J ;
Mooty, M ;
Nichani, S ;
Landman, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (01) :128-132
[5]  
Clark RB., 2009, Cumitech 31A, Verification and validation of procedures in the clinical microbiology laboratory
[6]  
Clinical and Laboratory Standards Institute, 2015, METH DILUT ANT SUSC
[7]   In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae [J].
Clock, Sarah A. ;
Tabibi, Setareh ;
Alba, Luis ;
Kubin, Christine J. ;
Whittier, Susan ;
Saiman, Lisa .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2013, 76 (03) :343-346
[8]  
CLSI (Clinical and Laboratory Standard Institute), 2016, Twenty-Second Informational Supplement.
[9]   Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? [J].
Daikos, G. L. ;
Markogiannakis, A. .
CLINICAL MICROBIOLOGY AND INFECTION, 2011, 17 (08) :1135-1141
[10]   Tigecycline: A glycylcycline antimicrobial agent [J].
Doan, Thien-Ly ;
Fung, Horatio B. ;
Mehta, Dhara ;
Riska, Paul F. .
CLINICAL THERAPEUTICS, 2006, 28 (08) :1079-1106